Tharimmune Gets FDA 505(b)(2) Path for TH104 but Faces Cash Crunch, Going-Concern Risk

Snapshot - Tharimmune, Inc. (NASDAQ: HILS)

Quick take:
Tharimmune is a clinical-stage biotech advancing TH104 (buccal film) and multiple biologic programs. The company received positive FDA feedback on a potential 505(b)(2) NDA pathway for TH104's new PrHPO indication (March 2025) - a clear program-level de-risk. Financially the company is burning cash, recently raised capital through PIPEs and ATMs, and reports substantial doubt about its ability to continue as a going concern.

Key facts & figures (from Form 10‑Q, periods ended June 30, 2025)
* Cash and cash equivalents: $2,241,980.
* Total assets: $2,530,166; Total liabilities: $2,162,807; Stockholders' equity: $367,359.
* Accumulated deficit: $(41,297,951).
* Net loss - three months ended June 30, 2025: $(1,855,153); six months: $(4,396,857).
* Net loss per share - three months: $(0.64); six months: $(1.61). Weighted average shares (six months): 2,725,863.
* Six‑month operating expenses: $4,397,829 (R&D $1,140,274; G&A $3,257,555).
* Cash used in operating activities (six months): $(3,831,531).
* Financing during six months: proceeds from June 2025 PIPE $2,500,000; ATM proceeds $266,625; net cash from financing $2,514,150.
* Note payable (PV): $249,716; insurance premium financing liability: $84,540.
* Shares outstanding (reported Aug 11, 2025): 4,635,251.
* Warrants issued in June 2025 PIPE: Series A 1,689,189; Series B 844,570 - total 2,533,759 warrants tied to that PIPE.

What's happening inside the company
* Clinical/Regulatory: Positive FDA feedback on TH104 PIND (PrHPO indication) - FDA indicated no additional clinical trials may be required for prophylactic dosing window and suggested a 505(b)(2) NDA path (still requires additional nonclinical work / CMC). This refocuses TH104 toward a nearer‑term NDA opportunity.
* Business development: Multiple licensing/collaboration deals in place (Avior, Intract, ABSI, Minotaur/Taurus) that expand the pipeline (TH103/TH104, TH023/infliximab oral delivery, IO bispecific candidates HS1940/HS3215).
* Capital markets: The company has been actively raising equity (June 2024/Dec 2024/June 2025 PIPEs and ATM sales). Management acknowledges substantial doubt on going concern and will need additional capital.

Income statement - positives
* Program focus & cost discipline: R&D spend declined materially vs prior year (six months R&D $1,140,274 vs $2,024,811 prior year - a 44% drop), meaning management is trimming preclinical/third‑party vendor costs and prioritizing near‑term regulatory path for TH104.
* Non‑cash support: Stock‑based compensation offsets cash burn (six months stock‑based comp ~$786,815), enabling retention/compensation without immediate cash outflow.
* No revenue dependence yet - transparent reporting of 0 revenue and focused use of equity financing to fund operations.

Income statement - negatives / risks
* Ongoing losses and cash burn: Six‑month net loss $(4.4M) and cash used in ops $(3.83M) with only $2.24M cash on the balance sheet - runway is limited.
* Going concern: Company explicitly states "substantial doubt" about ability to continue for at least one year without additional financing.
* Rising G&A: Six‑month G&A increased to $3.26M (up 21% YoY) - investor relations, director pay and some non‑R&D costs are pressuring burn.
* Dilution risk: Large outstanding warrant inventories (notably 2,533,759 warrants from June 2025) plus multiple pre‑funded warrants and future ATM/PIPE capacity mean sizeable potential dilution to shareholders.
* Low interest income: Interest income collapsed (six months $15,604 vs $149,508 prior year) reflecting much lower cash balances, which reduces non‑operating offsets to losses.

Key near‑term catalysts & watch list
* TH104 regulatory program: progress on the required nonclinical toxicology and CMC activities to support a 505(b)(2) NDA for PrHPO - timelines and costs are critical.
* Financing: additional equity/debt or strategic partnership required to fund operations - success and terms will determine dilution and runway.
* Clinical advancement of other assets (TH023, HS1940, HS3215) and milestone payments or partnerships from license agreements (Avior, Intract, ABSI, Minotaur/Taurus).
* Warrant exercises and ATM/PIP activity - monitor share count and cash inflows from exercises/sales.

Bottom line: Tharimmune has a meaningful programmatic catalyst (FDA pathway feedback for TH104) that could shorten time to regulatory filing, but the company is capital constrained. The balance sheet shows limited liquidity, ongoing losses, and meaningful dilution risk unless strategic financing or partnerships close on acceptable terms.